0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Research Report 2026
Published Date: 2026-02-04
|
Report Code: QYRE-Auto-37C12056
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global 10 Valent Pneumococcal Polysaccharide Vaccine Industry Research Report Growth Trends and Competitive Analysis 2022 2028
BUY CHAPTERS

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Research Report 2026

Code: QYRE-Auto-37C12056
Report
2026-02-04
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

23-Valent Pneumococcal Polysaccharide Vaccine Market Size

The global 23-Valent Pneumococcal Polysaccharide Vaccine market was valued at US$ 1323 million in 2025 and is anticipated to reach US$ 2600 million by 2032, at a CAGR of 10.3% from 2026 to 2032.

23-Valent Pneumococcal Polysaccharide Vaccine Market

23-Valent Pneumococcal Polysaccharide Vaccine Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on 23-Valent Pneumococcal Polysaccharide Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
Market Drivers:
The 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) market is driven by the increasing prevalence of pneumococcal infections, particularly among high-risk populations such as the elderly, children, and immunocompromised individuals. Governments and health organizations worldwide are promoting vaccination programs to reduce the burden of pneumococcal diseases, which has significantly boosted market growth. Additionally, rising awareness about the importance of preventive healthcare and advancements in vaccine manufacturing technologies contribute to the increased adoption of PPSV23 vaccines.
Market Challenges:
However, the market faces challenges such as the high cost of vaccination, which limits accessibility in low- and middle-income countries. Moreover, the competition from newer pneumococcal conjugate vaccines (PCVs), which offer broader coverage and are preferred for pediatric use, poses a threat to PPSV23's market share. Another concern is vaccine hesitancy and misinformation, which can hinder immunization efforts and impact the overall market growth.
Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.
This report delivers a comprehensive overview of the global 23-Valent Pneumococcal Polysaccharide Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding 23-Valent Pneumococcal Polysaccharide Vaccine. The 23-Valent Pneumococcal Polysaccharide Vaccine market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global 23-Valent Pneumococcal Polysaccharide Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of 23-Valent Pneumococcal Polysaccharide Vaccine Market Report

Report Metric Details
Report Name 23-Valent Pneumococcal Polysaccharide Vaccine Market
Accounted market size in 2025 US$ 1323 million
Forecasted market size in 2032 US$ 2600 million
CAGR 10.3%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Single Dose Vial
  • Pre-filled Syringe
by Application
  • For Children (Over 2 Years Old)
  • For Adult
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck, Sinovac, Kangtai Bio, CDIBP, Walvax
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines 23-Valent Pneumococcal Polysaccharide Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is 23-Valent Pneumococcal Polysaccharide Vaccine Market growing?

Ans: The 23-Valent Pneumococcal Polysaccharide Vaccine Market witnessing a CAGR of 10.3% during the forecast period 2026-2032.

What is the 23-Valent Pneumococcal Polysaccharide Vaccine Market size in 2032?

Ans: The 23-Valent Pneumococcal Polysaccharide Vaccine Market size in 2032 will be US$ 2600 million.

What is the Merck share in 23-Valent Pneumococcal Polysaccharide Vaccine Market?

Ans: Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%.

What is the 23-Valent Pneumococcal Polysaccharide Vaccine Market share by region?

Ans: The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.

Who are the main players in the 23-Valent Pneumococcal Polysaccharide Vaccine Market report?

Ans: The main players in the 23-Valent Pneumococcal Polysaccharide Vaccine Market are Merck, Sinovac, Kangtai Bio, CDIBP, Walvax

What are the Application segmentation covered in the 23-Valent Pneumococcal Polysaccharide Vaccine Market report?

Ans: The Applications covered in the 23-Valent Pneumococcal Polysaccharide Vaccine Market report are For Children (Over 2 Years Old), For Adult

What are the Type segmentation covered in the 23-Valent Pneumococcal Polysaccharide Vaccine Market report?

Ans: The Types covered in the 23-Valent Pneumococcal Polysaccharide Vaccine Market report are Single Dose Vial, Pre-filled Syringe

1 23-Valent Pneumococcal Polysaccharide Vaccine Market Overview
1.1 Product Definition
1.2 23-Valent Pneumococcal Polysaccharide Vaccine by Type
1.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Single Dose Vial
1.2.3 Pre-filled Syringe
1.3 23-Valent Pneumococcal Polysaccharide Vaccine by Application
1.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value by Application: 2025 vs 2032
1.3.2 For Children (Over 2 Years Old)
1.3.3 For Adult
1.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Estimates and Forecasts
1.4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue 2021–2032
1.4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales 2021–2032
1.4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 23-Valent Pneumococcal Polysaccharide Vaccine Market Competition by Manufacturers
2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of 23-Valent Pneumococcal Polysaccharide Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Date of Entry into the Industry
2.8 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Competitive Situation and Trends
2.8.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global 23-Valent Pneumococcal Polysaccharide Vaccine Players Market Share by Revenue
2.8.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Scenario by Region
3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021–2032
3.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021–2026
3.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2027–2032
3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2021–2032
3.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2021–2026
3.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2027–2032
3.4 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.4.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021–2032)
3.4.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.5.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021–2032)
3.5.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.7.1 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021–2032)
3.7.3 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021–2032)
4.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021–2026)
4.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027–2032)
4.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021–2032)
4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021–2032)
4.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021–2026)
4.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027–2032)
4.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021–2032)
5.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021–2026)
5.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027–2032)
5.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021–2032)
5.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021–2032)
5.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021–2026)
5.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027–2032)
5.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Merck 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Sinovac
6.2.1 Sinovac Company Information
6.2.2 Sinovac Description and Business Overview
6.2.3 Sinovac 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sinovac 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.2.5 Sinovac Recent Developments/Updates
6.3 Kangtai Bio
6.3.1 Kangtai Bio Company Information
6.3.2 Kangtai Bio Description and Business Overview
6.3.3 Kangtai Bio 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Kangtai Bio 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.3.5 Kangtai Bio Recent Developments/Updates
6.4 CDIBP
6.4.1 CDIBP Company Information
6.4.2 CDIBP Description and Business Overview
6.4.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.4.5 CDIBP Recent Developments/Updates
6.5 Walvax
6.5.1 Walvax Company Information
6.5.2 Walvax Description and Business Overview
6.5.3 Walvax 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Walvax 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.5.5 Walvax Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Chain Analysis
7.2 23-Valent Pneumococcal Polysaccharide Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process Analysis
7.4 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Marketing
7.4.1 23-Valent Pneumococcal Polysaccharide Vaccine Sales Channels
7.4.2 23-Valent Pneumococcal Polysaccharide Vaccine Distributors
7.5 23-Valent Pneumococcal Polysaccharide Vaccine Customer Analysis
8 23-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
8.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
8.2 23-Valent Pneumococcal Polysaccharide Vaccine Market Drivers
8.3 23-Valent Pneumococcal Polysaccharide Vaccine Market Challenges
8.4 23-Valent Pneumococcal Polysaccharide Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Competitive Situation by Manufacturers in 2025
 Table 4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market 23-Valent Pneumococcal Polysaccharide Vaccine Average Price (USD/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of 23-Valent Pneumococcal Polysaccharide Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Product Types and Applications
 Table 12. Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on 23-Valent Pneumococcal Polysaccharide Vaccine Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (K Units), 2021–2026
 Table 18. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021–2026)
 Table 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (K Units), 2027–2032
 Table 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2027–2032)
 Table 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (US$ Million), 2021–2026
 Table 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021–2026)
 Table 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (US$ Million), 2027–2032
 Table 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2027–2032)
 Table 25. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2021–2026
 Table 27. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2027–2032
 Table 28. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 29. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2021–2026
 Table 32. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2027–2032
 Table 33. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2021–2026
 Table 42. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2027–2032
 Table 43. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 50. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units) by Type (2021–2026)
 Table 51. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units) by Type (2027–2032)
 Table 52. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021–2026)
 Table 53. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2027–2032)
 Table 54. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021–2026)
 Table 57. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2027–2032)
 Table 58. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (USD/Unit) by Type (2021–2026)
 Table 59. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (USD/Unit) by Type (2027–2032)
 Table 60. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units) by Application (2021–2026)
 Table 61. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units) by Application (2027–2032)
 Table 62. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021–2026)
 Table 63. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2027–2032)
 Table 64. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021–2026)
 Table 67. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2027–2032)
 Table 68. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (USD/Unit) by Application (2021–2026)
 Table 69. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (USD/Unit) by Application (2027–2032)
 Table 70. Merck Company Information
 Table 71. Merck Description and Business Overview
 Table 72. Merck 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 73. Merck 23-Valent Pneumococcal Polysaccharide Vaccine Product
 Table 74. Merck Recent Developments/Updates
 Table 75. Sinovac Company Information
 Table 76. Sinovac Description and Business Overview
 Table 77. Sinovac 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 78. Sinovac 23-Valent Pneumococcal Polysaccharide Vaccine Product
 Table 79. Sinovac Recent Developments/Updates
 Table 80. Kangtai Bio Company Information
 Table 81. Kangtai Bio Description and Business Overview
 Table 82. Kangtai Bio 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 83. Kangtai Bio 23-Valent Pneumococcal Polysaccharide Vaccine Product
 Table 84. Kangtai Bio Recent Developments/Updates
 Table 85. CDIBP Company Information
 Table 86. CDIBP Description and Business Overview
 Table 87. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 88. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product
 Table 89. CDIBP Recent Developments/Updates
 Table 90. Walvax Company Information
 Table 91. Walvax Description and Business Overview
 Table 92. Walvax 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 93. Walvax 23-Valent Pneumococcal Polysaccharide Vaccine Product
 Table 94. Walvax Recent Developments/Updates
 Table 95. Key Raw Materials Lists
 Table 96. Raw Materials Key Suppliers Lists
 Table 97. 23-Valent Pneumococcal Polysaccharide Vaccine Distributors List
 Table 98. 23-Valent Pneumococcal Polysaccharide Vaccine Customers List
 Table 99. 23-Valent Pneumococcal Polysaccharide Vaccine Market Trends
 Table 100. 23-Valent Pneumococcal Polysaccharide Vaccine Market Drivers
 Table 101. 23-Valent Pneumococcal Polysaccharide Vaccine Market Challenges
 Table 102. 23-Valent Pneumococcal Polysaccharide Vaccine Market Restraints
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Product Picture of 23-Valent Pneumococcal Polysaccharide Vaccine
 Figure 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Share by Type: 2025 & 2032
 Figure 4. Single Dose Vial Product Picture
 Figure 5. Pre-filled Syringe Product Picture
 Figure 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Share by Application: 2025 & 2032
 Figure 8. For Children (Over 2 Years Old)
 Figure 9. For Adult
 Figure 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size (US$ Million), 2021–2032
 Figure 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Units), 2021–2032
 Figure 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price (USD/Unit), 2021–2032
 Figure 14. 23-Valent Pneumococcal Polysaccharide Vaccine Report Years Considered
 Figure 15. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Manufacturers in 2025
 Figure 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Manufacturers in 2025
 Figure 17. Top 5 and Top 10 Global 23-Valent Pneumococcal Polysaccharide Vaccine Players: Market Share by Revenue in 23-Valent Pneumococcal Polysaccharide Vaccine in 2025
 Figure 18. 23-Valent Pneumococcal Polysaccharide Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 20. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021–2032)
 Figure 21. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021–2032)
 Figure 22. United States 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 23. Canada 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021–2032)
 Figure 25. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021–2032)
 Figure 26. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. France 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Russia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021–2032)
 Figure 32. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021–2032)
 Figure 33. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Japan 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. India 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Australia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. China Taiwan 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Indonesia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Thailand 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Malaysia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021–2032)
 Figure 43. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021–2032)
 Figure 44. Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of 23-Valent Pneumococcal Polysaccharide Vaccine by Type (2021–2032)
 Figure 53. Global Revenue Market Share of 23-Valent Pneumococcal Polysaccharide Vaccine by Type (2021–2032)
 Figure 54. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (USD/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of 23-Valent Pneumococcal Polysaccharide Vaccine by Application (2021–2032)
 Figure 56. Global Revenue Market Share of 23-Valent Pneumococcal Polysaccharide Vaccine by Application (2021–2032)
 Figure 57. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (USD/Unit) by Application (2021–2032)
 Figure 58. 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS